Magnetic Resonance Guided Radiotherapy (MRgRT) For Cardiac Lymphomas: Case Report and New Perspectives

Author(s) :

Angela Romano1, Annarosa Cuccaro1, Eugenia De Marco2, Luca Boldrini1, Mauro Iafrancesco2, Francesco D’Alò1, Silvia Chiesa1, Ciro Mazzarella1, Stefan Hohaus1, Mario Balducci1

1 Dipartimento di Diagnostica per immagini, Radioterapia oncologica ed Ematologia – Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy

2 Dipartimento di Scienze Cardiovascolari- Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy

Corresponding author: Luca Boldrini, Email:

Published: Volume I, Issue 2 (December 2021) 80-85, , , - DOI: 10.53011/JMRO.2021.02.09

Open Access

Full text


December 27, 2021 0 Comments


Cardiac lymphomas are extremely rare and have poor prognoses. Currently, there are no established guidelines for treatment and the main approaches include surgery, chemotherapy (CHT), possibly combined with radiotherapy (RT), and autologous stem cell transplantation (ASCT). RT’s role is controversial and is not considered a standard approach. We describe the case of a patient diagnosed with cardiac lymphoblastic B- cell lymphoma/ acute Lymphoblastic B-cell leukemia and successfully treated with a multimodality approach, including CHT, RT, and ASCT. In particular, the patient was referred to magnetic resonance-guided RT (MRgRT), currently the most advanced available technology in the RT field, which maximizes therapeutic efficacy by exploiting the best soft-tissue resolution of the magnetic resonance images and efficient gating protocols during treatment delivery.

Figure 1. CT (left) and cardiac MRI (right) staging images. The lesion is indicated by red arrows
Figure 2. Segmentation of target volume and organs at risk (OARs) on axial, sagittal, and coronal TRUFI simulation scans. The gross tumor volume (GTV) is highlighted in red.
Figure 3. 18F-FDG PET-CT scan: staging (A), one month (B), and eight months (C) after RT re- evaluation
Notify of
Inline Feedbacks
View all comments